A research agenda for malaria eradication: drugs

malERA Consultative Group on Drugs, Pedro L Alonso, Quique Bassat, Fred Binka, Thomas Brewer, Richa Chandra, Janice Culpepper, Rhoel Dinglasan, Ken Duncan, Stephan Duparc, Mark Fukuda, Ramanan Laxminarayan, John R MacArthur, Alan Magill, Carol Marzetta, Jessica Milman, Theonest Mutabingwa, François Nosten, Solomon Nwaka, Myaing Nyunt, Colin Ohrt, Christopher V Plowe, John Pottage, Ric Price, Pascal Ringwald, Andrew Serazin, Dennis Shanks, Robert Sinden, Marcel Tanner, Henri Vial, Steven A Ward, Thomas E Wellems, Timothy Wells, Nicholas White, Dyann Wirth, Shunmay Yeung, Yongyuth Yuthavong, Pedro L Alonso, Abdoulaye Djimde, Alan Magill, Jessica Milman, José Nájera, Christopher V Plowe, Timothy Wells, Shunmay Yeung, Peter Kremsner, Ivo Mueller, Robert D Newman, Regina Rabinovich, malERA Consultative Group on Drugs, Pedro L Alonso, Quique Bassat, Fred Binka, Thomas Brewer, Richa Chandra, Janice Culpepper, Rhoel Dinglasan, Ken Duncan, Stephan Duparc, Mark Fukuda, Ramanan Laxminarayan, John R MacArthur, Alan Magill, Carol Marzetta, Jessica Milman, Theonest Mutabingwa, François Nosten, Solomon Nwaka, Myaing Nyunt, Colin Ohrt, Christopher V Plowe, John Pottage, Ric Price, Pascal Ringwald, Andrew Serazin, Dennis Shanks, Robert Sinden, Marcel Tanner, Henri Vial, Steven A Ward, Thomas E Wellems, Timothy Wells, Nicholas White, Dyann Wirth, Shunmay Yeung, Yongyuth Yuthavong, Pedro L Alonso, Abdoulaye Djimde, Alan Magill, Jessica Milman, José Nájera, Christopher V Plowe, Timothy Wells, Shunmay Yeung, Peter Kremsner, Ivo Mueller, Robert D Newman, Regina Rabinovich

Abstract

Antimalarial drugs will be essential tools at all stages of malaria elimination along the path towards eradication, including the early control or "attack" phase to drive down transmission and the later stages of maintaining interruption of transmission, preventing reintroduction of malaria, and eliminating the last residual foci of infection. Drugs will continue to be used to treat acute malaria illness and prevent complications in vulnerable groups, but better drugs are needed for elimination-specific indications such as mass treatment, curing asymptomatic infections, curing relapsing liver stages, and preventing transmission. The ideal malaria eradication drug is a coformulated drug combination suitable for mass administration that can be administered in a single encounter at infrequent intervals and that results in radical cure of all life cycle stages of all five malaria species infecting humans. Short of this optimal goal, highly desirable drugs might have limitations such as targeting only one or two parasite species, the priorities being Plasmodium falciparum and Plasmodium vivax. The malaria research agenda for eradication should include research aimed at developing such drugs and research to develop situation-specific strategies for using both current and future drugs to interrupt malaria transmission.

Conflict of interest statement

No competing interests: PA, AD, AM, JM, JN, CP, RR, SY, PK. TW works for the Medicines for Malaria Venture, who are sponsoring or cosponsoring some of the projects discussed in the meetings.

References

    1. Chanda P, Hamainza B, Mulenga S, Chalwe V, Msiska C, et al. Early results of integrated malaria control and implications for the management of fever in under-five children at a peripheral health facility: A case study of Chongwe rural health centre in Zambia. Malar J. 2009;8:49.
    1. United Arab Emirates certified malaria-free. Wkly Epidemiol Rec. 2007;82:30–32.
    1. Plowe CV. The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg. 2009;103:S11–S14.
    1. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: Preventing and overcoming ‘vaccine resistant malaria’. Parasite Immunol. 2009;31:560–573.
    1. Kelly-Hope L, Ranson H, Hemingway J. Lessons from the past: managing insecticide resistance in malaria control and eradication programmes. Lancet Infect Dis. 2008;8:387–389.
    1. Plowe CV, Alonso P, Hoffman SL. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis. 2009;200:1646–1649.
    1. The Roll Back Malaria Partnership. Geneva: The Roll Back Malaria Partnership; 2010. The global malaria action plan for a malaria-free world.
    1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. Vivax malaria: Neglected and not benign. Am J Trop Med Hyg. 2007;77:79–87.
    1. Marsh K. Malaria–a neglected disease? Parasitology. 1992;104:S53–S69.
    1. Song J, Socheat D, Tan B, Dara P, Deng C, et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J. 2010;9:57.
    1. Alker AP, Lim P, Sem R, Shah NK, Yi P, et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg. 2007;76:641–647.
    1. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–467.
    1. Nyunt MM, Plowe CV. Pharmacologic advances in the global control and treatment of malaria: Combination therapy and resistance. Clin Pharmacol Ther. 2007;82:601–605.
    1. Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A. 2008;105:14216–14221.
    1. Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, et al. World Antimalarial Resistance Network (WARN) I: Clinical efficacy of antimalarial therapy. Malar J. 2007;6:119.
    1. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis. 2008;46:165–171.
    1. Najera JA. Malaria control: Achievements, problems and strategies. Parassitologia. 2001;43:1–89.
    1. Feachem RGA. San Francisco: The Global Health Group, UCSF Global Health Sciences; 2010. Shrinking the malaria map: A guide on malaria elimination for policy makers. Chapter 6.
    1. Snowden FM. New Haven: Yale University Press; 2005. The conquest of malaria. Italy 1900-1962.
    1. Bruce-Chwatt LJ. Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology. Bull World Health Organ. 1959;21:737–772.
    1. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, et al. Malaria eradication on islands. Lancet. 2000;356:1560–1564.
    1. von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol. 2003;19:452–460.
    1. Molineaux L, Gramiccia G. Geneva: World Health Organization; 1980. The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa.
    1. Han ET, Lee DH, Park KD, Seok WS, Kim YS, et al. Reemerging vivax malaria: Changing patterns of annual incidence and control programs in the Republic of Korea. Korean J Parasitol. 2006;44:285–294.
    1. Dola SK. Mass drug administration as a supplementary attack measure in malaria eradication programme. East Afr Med J. 1974;51:529–531.
    1. Pinotti M. A new method of malaria prophylaxis: The addition of an antimalarial drug to cooking salt used in daily preparation of food. Rev Brasil Malariol. 1954;6:5–12.
    1. Peters W. London: Academic Press; 1970. Chemotherapy and drug resistance in malaria.
    1. Clyde DF. WHO/MAL/506.65. Geneva: World Health Organization; 1965. Duration of antimalarial activity of cycloguanil pamoate amond semi-immune Africans in Tanzania.
    1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–2620.
    1. The malERA Consultative Group on Vaccines. A research agenda for malaria eradication: Vaccines. PLoS Med. 2011:e1000398. doi: .
    1. Peters W. A malaria survey in the Western District of Papua. P N G Med J. 1957;2:25–38.
    1. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature. 1995;376:246–249.
    1. Cortese JF, Caraballo A, Contreras CE, Plowe CV. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis. 2002;186:999–1006.
    1. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria. Parasitol Today. 1996;12:399–401.
    1. Nyunt MM, Hendrix CW, Bakshi RP, Kumar N, Shapiro TA. Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2009;80:528–535.
    1. Dondorp AM, Yeung S, White L, Nguon C, Day NP, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272–280.
    1. The malERA Consultative Group on Modeling. A research agenda for malaria eradication: Modeling. PLoS Med. 2011:e1000403. doi: .
    1. The malERA Consultative Group on Health Systems and Operational Research. A research agenda for malaria eradication: Health systems and operational research. PLoS Med. 2011:e1000397. doi: .
    1. The malERA Consultative Group on Monitoring, Evaluation, and Surveillance. A research agenda for malaria eradication: Monitoring, evaluation, and surveillance. PLoS Med. 2011:e1000400. doi: .
    1. The malERA Consultative Group on Integration Strategies. A research agenda for malaria eradication: Cross-cutting issues for eradication. PLoS Med. 2011:e1000404. doi: .

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera